Vertex Pharmaceuticals Inc. said it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients’ lung function in late-stage studies. The drug, a combination of the compounds tezacaftor and ivacaftor, is intended to treat patients who have one or two copies of a genetic mutation that is the most common cause of cystic fibrosis, a progressive lung disease that affects...

Source: Wall Street Journal March 28, 2017 21:11 UTC